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O
pen access is gaining 
momentum. Authors are 
submitting papers in ever-
increasing numbers to open-access 
journals. Several prominent research 
sponsors, including the Wellcome 
Trust, the Max Planck Society, the 
Centre National de la Recherche 
Scientiﬁ  que (CNRS), and the 
Institut National de la Santé et de la 
Recherche (INSERM), have recently 
pronounced that open access is the 
best way for the researchers they 
support to publish their work. Several 
established commercial and not-for-
proﬁ  t publishers have announced plans 
to experiment with open-access models 
for some or all of their journals. 
Delighted and encouraged, we gear 
up for the launch of PLoS Medicine this 
autumn—the next step in our efforts 
to bring the beneﬁ  ts of open access 
to the entire scientiﬁ  c and medical 
community. We aim to make PLoS 
Medicine a premier journal, providing 
open access to the best medical 
research to researchers, to physicians 
and other caregivers, and to the public. 
The case for open access to medical 
research is even stronger than it is for 
basic research in biology. There are 
more interested parties: patients and 
their advocates; biotechnology and 
pharmaceutical companies that develop 
drugs and medical devices; doctors, 
nurses, and other healthcare providers; 
and health policy-makers at the 
national and international levels. The 
goal of the medical research enterprise 
is—or should be—scientiﬁ  cally, 
ethically, and socially responsible 
medicine, which means research that 
will beneﬁ  t patients worldwide. 
The reality looks somewhat different. 
Large investments into basic research 
have not yet lived up to their full 
potential to save lives and improve their 
quality. Doctors, patients, and their 
advocates do not have ready access to 
the combined peer-reviewed evidence 
from medical research. The prices for 
the latest drugs often put them out 
of reach of patients in poor countries 
or poor patients in countries without 
universal healthcare systems. Moreover, 
research focuses disproportionately 
on the potentially lucrative treatments 
for diseases of wealthy societies, 
shortchanging the poorer countries, 
which bear the greatest burden of 
disease. 
A medical journal by itself cannot 
change this reality. But with the help of 
researchers and practicing physicians 
around the world who recognize the 
need and opportunity for change, we 
seek to create a journal that promotes 
medical research and practice that 
is both scientiﬁ  cally rigorous and 
compassionate. 
Open access to this literature will 
strengthen the medical research 
community by giving all stakeholders 
free and immediate access to the latest 
medical research, along with new 
and more powerful search tools and 
links between the literature and other 
relevant information. 
PLoS Medicine will be an 
international, modern, general 
medical journal, covering all areas 
in the medical sciences, from basic 
studies to large clinical trials and 
cost-effectiveness analyses. We will 
concentrate on human studies that 
enhance our understanding of disease 
epidemiology, etiology, and physiology; 
the development of prognostic and 
diagnostic technologies; and trials 
that test the efﬁ  cacy of speciﬁ  c 
interventions and those that compare 
different treatments. We will publish 
original research and commentary 
that promotes translation both of basic 
research into clinical investigation and 
of clinical evidence into practice. 
A truly broad medical journal is an 
ambitious project, but we want PLoS 
Medicine to promote an integrated 
understanding of the patient—to make 
it easy for people to read outside their 
specialty area. “Doctors are systems 
biologists,” as one medical researcher 
put it, and inspiration can often be 
found in unfamiliar territory. 
Articles published in PLoS Medicine 
will be rigorously peer-reviewed. 
Academic and professional editors, 
supported by expert peer-reviewers, will 
select those studies that drive research 
forward—in this case, toward medical 
applications and beneﬁ  ts for patients. 
This issue of PLoS Biology contains 
two “human” studies that met 
our criteria for excellence and 
originality, a paper by Howard Chang 
and colleagues (found at DOI: 
10.1371/journal.pbio.0020007) on 
the microarray analysis of tumors 
and one by Sarah Rowland-Jones 
and coworkers (found at DOI: 
10.1371/journal.pbio.0020020) 
that examines how HIV exhausts 
the capacity of the immune system. 
Similar papers submitted in the future 
will be published in PLoS Medicine, 
alongside studies that have more direct 
implications for clinical practice. This 
issue also contains several articles 
describing more basic advances with 
medical implications: a study by Terry 
van Dyke and colleagues (found at 
DOI: 10.1371/journal.pbio.0020022) 
describing a new mouse model for 
breast cancer, a report on a novel 
approach to drug synthesis by Chaitan 
Khosla and coworkers (found at DOI: 
10.1371/journal.pbio.0020031), and an 
article by Stephen Dowdy et al. (found 
at DOI: 10.1371/journal.pbio.0020036) 
on targeted modulation of p53 activity. 
PLoS Biology will continue to solicit and 
publish such articles, but we will bring 
them—and similar ones published 
elsewhere—to the attention of the 
readers of PLoS Medicine.
Like PLoS Biology, PLoS Medicine must 
be a community journal to achieve 
its goals. If you are a researcher or 
an individual anywhere in the world 
who has a stake in medical research 
and if the goals of PLoS Medicine 
outlined here resonate with you, please 
contact us. PLoS Medicine will accept 
submissions beginning in April 2004, 
and we are looking for advocates 
who will help to spread the word 
about open access and PLoS Medicine 
in the global medical community 
and for investigators who will submit 
excellent research, review submitted 
articles, and contribute editorials and 
commentaries. PLoS Medicine is and 
will stay a work in progress, and we 
want to consult with as many people as 
possible, both before the launch and as 
PLoS Medicine evolves. Sign up to join 
the PLoS Medicine community at http:
⁄⁄www.plos.org/medicine and help us 
to make the best of medical research 
and practice accessible to a global 
audience.  
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